Latest Headlines

Latest Headlines

UPDATED: FDA panel recommends approval of Alcon intraocular lens

FDA's Ophthalmic Devices Advisory Committee panel overwhelming recommended PMA approval of Alcon's ReSTOR Multifocal Toric Intraocular Lens for patients undergoing cataract eye surgery who are astigmatic and suffer from presbyopia.

300 Novartis workers to be sacked when Alcon plant closes next year

Workers at the plant in Mississauga, Ontario, got the news that layoffs will begin in May and operations will wind down by the end of next year.

'Zorro' claims Novartis' Alcon unit faked trials to bribe Chinese docs

The bribery allegations in China just keep on coming. Novartis' Alcon eyecare division now says it will investigate claims it used fabricated clinical trials to bribe doctors. The news is none too welcome for Novartis, which has already faced a set of bribery accusations in China.

Minority Schering shareholders extract another €46 per share from Bayer

A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.

Novartis nabs EU clearance for Jetrea; Roche's hep C drug Pegasys wins new use

Novartis won European approval for its eye drug Jetrea, as a treatment for vitreomacular traction, and the European Medicines Agency also approved a new use for Roche's hepatitis C drug Pegasys.

FDA knocks Alcon for marketing updated cataract laser minus clearance

Alcon marketed its LenSx laser to treat cataracts without gaining proper regulatory clearance for updated software and other improvements to the product, the FDA alleges in a warning letter citing the company.

Novartis' Jimenez says no need to sell Roche stake

With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.

Novartis faces probes on Tekturna tactics, Iran sales

Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.

Novartis unit buys SensoMotoric's eye surgery tech

Alcon, Novartis' eye-care unit, has bought German company SensoMotoric Instruments' opthalmic business, acquiring technology for cataract surgery.

Novartis grabs rights to eye drug in $494M deal

Belgian biotech ThromboGenics ($ THR) has picked up a major partnership with the  Alcon  unit of Swiss drug giant Novartis ($NVS) for its experimental therapeutic for an eye ailment known as symptomatic vitreomacular adhesion, or VMA. And the deal with Alcon, which grants rights to market the eye drug outside the U.S., could be worth up to €375 million ($494 million) to ThromboGenics.